Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer
Conclusion: SG demonstrates remarkable preclinical activity against biologically aggressive and chemotherapy-resistant EOC cell lines and a significant bystander effect against EOC cell lines with heterogenous Trop-2 expression. Clinical trials are warranted.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Chromium | Clinical Trials | Epithelial Cancer | Ovarian Cancer | Ovaries | Study